Sermorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates your pituitary gland to produce its own growth hormone. Unlike synthetic HGH, sermorelin preserves your body's natural feedback mechanisms and pulsatile secretion patterns.
Sermorelin is on hold and not currently prescribed while we confirm pharmacy eligibility. This page is educational only.
Sermorelin is a synthetic peptide consisting of the first 29 amino acids of GHRH — the hormone your hypothalamus releases to signal your pituitary to make growth hormone. When injected, it stimulates the anterior pituitary to produce and release growth hormone in its natural pulsatile pattern. Unlike direct HGH injections, sermorelin works with your body's feedback system rather than overriding it.
Growth hormone levels decline approximately 14% per decade after age 30. Sermorelin therapy aims to restore more youthful GH output without the risks of supraphysiologic doses of exogenous HGH.
Honest framing: Individual results vary significantly. Sermorelin is not FDA-approved for anti-aging and is used off-label for GH optimization. Benefits develop gradually over 3–6 months.
For general education, a typical published protocol is subcutaneous self-injection before bed (when natural GH pulses are strongest), 5 days on / 2 days off, for 3–6 month cycles with periodic breaks. Dosing is individualized by a physician based on goals, labs (including baseline IGF-1), and response.
Generally well-tolerated. Possible side effects include injection site reactions (redness, swelling), headache, flushing, dizziness. Rare: joint pain, numbness/tingling (similar pattern to elevated GH).
Sermorelin is on hold and not currently prescribed while we confirm pharmacy eligibility. We are not accepting sermorelin requests at this time, and no price is offered. If you are interested in longevity care, a physician can discuss the options we currently prescribe.
Medical disclaimer: Off-label use. Educational content. Page medically reviewed by Teja V. Surapaneni, MD, MS (NV, WA, OR, WI). Last reviewed: April 17, 2026